Physician profile
Pete L Caples
NPI 1720065766
$1,586.90
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $409 · 2021: $473.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $360.27 | 2019-2021 | |
| Amgen INC. | $297.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $203.54 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $140.98 | 2019-2021 | |
| Bardy Diagnostics, INC. | $135.00 | 2020-2021 | |
| Philips North America LLC | $83.75 | 2020 | |
| Amarin Pharma, INC. | $69.10 | 2019-2021 | |
| Braemar Manufacturing, LLC | $57.26 | 2019 | |
| Novo Nordisk INC | $32.13 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.60 | 2019-2020 | |
| Astellas Pharma US INC | $31.00 | 2019-2021 | |
| Boston Scientific Corporation | $27.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.30 | 2021 | |
| Portola Pharmaceuticals, LLC | $23.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.20 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.37 | 2019 | |
| Medtronic, INC. | $15.26 | 2021 | |
| Pfizer INC. | $12.36 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pete Caples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.